Home LiteratureArticle Details
PMID: 20425006 Published · ppublish English Journal Article Review

Inflammasome and IL-1beta-mediated disorders.

Current allergy and asthma reports ·Vol. 10 ·No. 4 ·2010-07-00 ·Pages 229-35

Hoffman HM, Wanderer AA

Abstract

The NLRP3 inflammasome is an intracellular complex that regulates the release of proinflammatory cytokines such as interleukin-1beta in response to exogenous pathogens and endogenous danger signals. Evidence from studies involving human genetics, human ex vivo mononuclear cell responses, and in vivo and in vitro murine models confirms the importance of the inflammasome and interleukin-1beta in the pathogenesis of several inherited and complex diseases. The availability of several effective interleukin-1beta targeted therapies has allowed for successful proof-of-concept studies in several of these disorders. However, many other diseases are likely to be mediated by the inflammasome and interleukin-1beta, providing additional targets in the future.

MeSH Terms
Animals Asbestosis/drug therapy Carrier Proteins/immunology Cryopyrin-Associated Periodic Syndromes/immunology Diabetes Mellitus, Type 2/drug therapy,immunology Gout/drug therapy,immunology Humans Inflammation/drug therapy,immunology Interleukin-1beta/antagonists & inhibitors,immunology Lung Diseases/drug therapy Mice NLR Family, Pyrin Domain-Containing 3 Protein Silicosis/drug therapy
Chemicals
Carrier Proteins Interleukin-1beta NLR Family, Pyrin Domain-Containing 3 Protein NLRP3 protein, human
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Hoffman Hal M
Division of Allergy and Immunology, University of California at San Diego and Rady Children's Hospital of San Diego, La Jolla, CA 92093, USA. [email protected]
Wanderer Alan A
References (32)
32 references, click to expand
  1. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.
    Arthritis Rheum. 2008 Aug;58(8):2443-52 PMID: 18668535
  2. Treatment of familial Mediterranean fever with anakinra.
    Ann Intern Med. 2007 Jun 5;146(11):825-6 PMID: 17548423
  3. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    J Clin Rheumatol. 2009 Jun;15(4):161-4 PMID: 19363453
  4. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.
    Ann Rheum Dis. 2006 Apr;65(4):542-4 PMID: 16096327
  5. Interleukin-1 beta targeted therapy for type 2 diabetes.
    Expert Opin Biol Ther. 2009 Sep;9(9):1177-88 PMID: 19604125
  6. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra.
    Br J Dermatol. 2009 Nov;161(5):1199-201 PMID: 19673875
  7. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica.
    Cytokine. 1993 Jan;5(1):57-61 PMID: 7683505
  8. Developments in the scientific and clinical understanding of gout.
    Arthritis Res Ther. 2008;10(5):221 PMID: 18947374
  9. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*).
    Annu Rev Immunol. 2009;27:621-68 PMID: 19302049
  10. Rationale for IL-1beta targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease.
    J Pediatr Hematol Oncol. 2009 Aug;31(8):537-8 PMID: 19636265
  11. Beneficial response to interleukin 1 receptor antagonist in traps.
    Am J Med. 2004 Aug 1;117(3):208-10 PMID: 15300976
  12. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS).
    Expert Opin Biol Ther. 2009 Apr;9(4):519-31 PMID: 19344287
  13. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.
    Arthritis Rheum. 2007 Apr;56(4):1273-1285 PMID: 17393462
  14. Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
    Nat Rev Rheumatol. 2009 Oct;5(10):529-30 PMID: 19798026
  15. The inflammasomes: guardians of the body.
    Annu Rev Immunol. 2009;27:229-65 PMID: 19302040
  16. Anakinra for rheumatoid arthritis: a systematic review.
    J Rheumatol. 2009 Jun;36(6):1118-25 PMID: 19447938
  17. Rationale for IL-1beta-targeted therapy to minimize hypoxic-ischemic encephalopathy.
    J Perinatol. 2009 Dec;29(12):785-7 PMID: 19935731
  18. Use of canakinumab in the cryopyrin-associated periodic syndrome.
    N Engl J Med. 2009 Jun 4;360(23):2416-25 PMID: 19494217
  19. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.
    Ann Rheum Dis. 2009 Oct;68(10):1613-7 PMID: 19635719
  20. Thioredoxin-interacting protein links oxidative stress to inflammasome activation.
    Nat Immunol. 2010 Feb;11(2):136-40 PMID: 20023662
  21. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.
    Nat Genet. 2001 Nov;29(3):301-5 PMID: 11687797
  22. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.
    N Engl J Med. 2009 Jun 4;360(23):2426-37 PMID: 19494218
  23. Sunburned skin activates inflammasomes.
    Trends Cell Biol. 2008 Jan;18(1):4-8 PMID: 18083030
  24. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.
    Mol Cell. 2002 Aug;10(2):417-26 PMID: 12191486
  25. Corticosteroid resistance in pulmonary neutrophilic inflammatory disorders and rationale for adjunct IL-1beta targeted therapy.
    Am J Respir Cell Mol Biol. 2009 Aug;41(2):246-7 PMID: 19620408
  26. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.
    Lancet. 2004 Nov 13-19;364(9447):1779-85 PMID: 15541451
  27. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis.
    Am J Respir Crit Care Med. 2009 May 15;179(10):903-13 PMID: 19218193
  28. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica.
    Science. 2008 May 2;320(5876):674-7 PMID: 18403674
  29. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity.
    J Invest Dermatol. 2007 Aug;127(8):1956-63 PMID: 17429439
  30. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Ann Rheum Dis. 2008 Mar;67(3):302-8 PMID: 17947302
  31. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.
    J Inherit Metab Dis. 2006 Dec;29(6):763 PMID: 17103011
  32. Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS).
    Rheumatology (Oxford). 2007 Dec;46(12):1865-6 PMID: 17967816
Article Info
Journal
Current allergy and asthma reports
Abbr.
Curr Allergy Asthma Rep
ISSN
1534-6315
DOI
10.1007/s11882-010-0109-z
Email
[email protected]
Published
2010-07-00
Pages
229-35
Language
English
Region
United States
NLM ID
101096440
PMCID
PMC2892083
Subset
IM
External Links
PubMed source DOI: 10.1007/s11882-010-0109-z PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2